Sanofi plucks three more NK cell engagers from French biotech partner, putting down €25M cash
Having sent one natural killer cell engager into the clinic and plotted an IND path for a second, Sanofi is returning to a biotech partner for more.
This time around, Sanofi wants from Innate Pharma a candidate that targets B7H3 — an emerging potential checkpoint in immuno-oncology — as well as options for two more targets. As with its last deal, Sanofi will be responsible for all development, manufacturing and commercialization once Innate produces the programs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.